Boltz Raises $110M Series a Led by Bessemer for Drug Discovery AI
Summary
Boltz PBC raises a $110 million Series A led by Bessemer to speed small molecule drug discovery with its BoltzMol-1 and BoltzProt-1 models, sold per token through an API. Boltz says six of the world's 20 largest drugmakers are clients and token use has grown 50-fold since June. Boltz plans to spend the funds on headcount and computing infrastructure.
Key Points
- Boltz says BoltzMol-1 found small molecule hits for six of 10 challenging targets in its internal tests.
- Greycroft, Andreessen Horowitz, Amplify Partners, F-Prime Capital and Hummingbird join Bessemer in the Series A.
- Boltz has begun training a new generation of molecule design algorithms that it says show substantial improvements over its current models.